February 13, 2018 / 9:42 PM / 4 days ago

BRIEF-Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat For The Treatment Of People With Prodromal Alzheimer’S Disease

Feb 13 (Reuters) - Merck & Co Inc:

* MERCK ANNOUNCES DISCONTINUATION OF APECS STUDY EVALUATING VERUBECESTAT (MK-8931) FOR THE TREATMENT OF PEOPLE WITH PRODROMAL ALZHEIMER’S DISEASE

* MERCK & CO INC - ‍EDMC CONCLUDED THAT IT WAS UNLIKELY THAT POSITIVE BENEFIT/RISK COULD BE ESTABLISHED IF TRIAL CONTINUED​

* MERCK & CO INC - ‍DECISION TO STOP STUDY FOLLOWS A RECOMMENDATION BY EXTERNAL DATA MONITORING COMMITTEE​

* MERCK & CO INC - ‍IT WILL BE STOPPING PROTOCOL 019, ALSO KNOWN AS APECS STUDY​

* MERCK & CO INC - ‍STOPPING PROTOCOL 019, ALSO KNOWN AS APECS STUDY, A PHASE 3 STUDY EVALUATING VERUBECESTAT (MK-8931)​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below